Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Salesforce (CRM) initiated with a Hold at Needham by analyst Scott Berg, who cites decelerating organic revenue growth, a looming sales reorganization, and an operating model not profitable enough at its revenue to drive valuation higher. 2. BioCryst (BCRX) initiated with a Buy at Ladenburg by analyst Christopher James, who thinks the company is poised to become a leading oral drug rare disease company. 3. Seaport Global analyst Josh Sullivan started CACI (CACI) International with a Buy rating and $140 price target. The company has broad exposure to trends in fiscal/defense spending, the analyst contends. 4. Citi analyst Walter Pritchard started OpenText (OTEX) with a Neutral rating and $36 price target, stating that the current valuation already reflects the potential of the ECD acquisition. 5. Albireo Pharma (ALBO) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Stifel analyst Bert Subin raised the firm's price target on CACI to $430 from $390 and keeps a Buy rating on the shares. CACI "remains on a roll, winning various new contracts and task orders," says the analyst, who adds CACI remains the firm's top picks in the core government services sector. The firm has increased estimates for FY24, but "more so for FY25," to reflect new awards with additional upside potential from intel spending, the analyst tells investors.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here